Actavis to purchase four marketed products from Akorn and Hi-Tech Pharmacal Actavis (ACT) announced that it has entered into agreements with Akorn (Akrx) and Hi-Tech Pharmacal (HITK) to purchase four currently marketed products and one product under development for cash consideration. The closing of the purchase agreements are contingent upon the consummation of Akorn's acquisition of Hi-Tech. Financial terms of the agreements were not disclosed. The agreements include three products marketed under Abbreviated New Drug Applications and one product marketed under a New Drug Application: Lidocaine/Prilocaine Topical Cream. The agreements also include one product under development.
Akorn launches Myorisan 30 mg Capsules Akorn announced that it has launched the recently-approved 30 mg strength of Myorisan. This launch further builds the Myorisan product portfolio that also includes 10 mg, 20 mg and 40 mg capsules.